StratumSkin science, cited
Ingredient Index

PCOS-driven acne & hirsutism · Ingrown hairs (pseudofolliculitis barbae)

Eflornithine

Prescription topical, brand name Vaniqa

Overall grade BTypical strength 13.9% cream, twice daily3 sources

The best-evidenced topical option specifically for unwanted facial hair, backed by the kind of large, double-blind, vehicle-controlled trials that earned it FDA approval. The honest caveat that gets lost in the marketing: it slows hair regrowth, it does not remove hair or treat what's causing it, and the effect fades within weeks of stopping. It's a maintenance cream, not a cure, and it's usually paired with a hair-removal method rather than replacing one. That combination role is also its best-evidenced use in razor bumps: paired with laser hair removal, it measurably outperforms laser alone.

Claim by claim

BReduces facial hair growth rateTwo pivotal double-blind, vehicle-controlled trials (18 centres, n≈594) found a significant reduction in growth on physician and subject assessment over 24 weeks.
BPatient-reported bother/discomfortA secondary analysis of the same trial population found 62% of treated subjects reported clinically meaningful improvement vs. 35% on vehicle.
DRemoves hair or treats the underlying causeIt doesn't. Growth resumes within roughly 8 weeks of stopping, which is why it's a maintenance product used alongside removal, not instead of it.
BBoosts laser hair removal for razor bumps (pseudofolliculitis barbae)In a small but properly randomised, double-blind, placebo-controlled trial in 27 men, adding this cream to standard laser sessions produced a median 99.5% reduction in hair count and inflammatory bumps at 16 weeks, against 85% for laser plus a placebo cream on the paired side of the same neck. One trial, not yet repeated, but a real within-person comparison rather than a between-group one, which controls for a lot of the usual noise.

References

  1. Wolf JE, et al.; Eflornithine HCl Study Group. Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair. International Journal of Dermatology, 2007.BTwo multicentre, double-blind, randomised, vehicle-controlled trials, 18 centres, n≈594·The pivotal trials behind FDA approval. We could not cleanly separate this paper's full author list and page numbers from a closely related companion paper (below) during our research, so treat the exact citation details as needing one more check before quoting page numbers.PubMed 17214730
  2. Jackson J, Caro JJ, Caro G, et al.; Eflornithine HCl Study Group. The effect of eflornithine 13.9% cream on the bother and discomfort due to hirsutism. International Journal of Dermatology, 2007.BSecondary patient-reported-outcomes analysis of the same pivotal-trial population·Using a validated bother/discomfort instrument, 62.1% of treated subjects reported clinically meaningful improvement vs. 35.3% on vehicle.PubMed 17822506
  3. Xia Y, Cho S, Howard RS, Maggio KL. Topical eflornithine hydrochloride improves the effectiveness of standard laser hair removal for treating pseudofolliculitis barbae: a randomized, double-blinded, placebo-controlled trial. Journal of the American Academy of Dermatology, 2012.BRandomised, double-blind, placebo-controlled, within-person split-neck (contralateral-side) trial, n=27 men·Conducted through a U.S. military dermatology programme; no funding tie to eflornithine's manufacturer found in available sources. Each participant received laser on both sides of the neck, with eflornithine cream on one side and a placebo cream on the other, which is a stronger design than comparing two separate groups of people.PubMed 22226431DOI 10.1016/j.jaad.2011.10.029

Your turn

Did this hold up? Tell us honestly — especially if it didn’t.

Anonymous. Stored in your browser.

The Sunday study

One paper a week, explained properly

We pick a single new study, tell you what it measured, how many people it measured it in, and whether it should change anything you're doing — plus the two articles we published that week. No panic, and no hype.

We don't recommend products yet. When we do, they'll be things you can actually buy in India, any affiliate link will be labelled as one, and a commission will never buy a recommendation.

One email each Sunday. Unsubscribe in one click.